Feature BioSight developing non-toxic drug against leukemia By Len Zehr Closely-held BioSight is in clinical development with its lead chemotherapy drug, Astarabine, as a non-toxic treatment for hematologic malignancies, including acute myeloid leukemia (AML). “Treatment and... January 5, 2016